ClinicalTrials.gg
CompletedNCT05218694CT-FOCIUpdated Aug 26, 2026

Coronary Computed Tomography Angiography For Optimized Invasive Coronary examInation

An interventional study of CCTA guided focused coronary angiography examination. in Ischemic Heart Disease and Coronary Artery Disease, sponsored by Aarhus University Hospital Skejby. Completed at 1 site in Denmark. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-26.

Primary conditionCoronary Artery DiseaseRegistry: Myocardial IschemiaReclassifiedWhy we changed it
Registry
Myocardial Ischemia — the first condition term the registry derived for this study.
ClinicalTrials.gg
Coronary Artery Disease
Why
  1. The study's listed conditions name Coronary Artery Disease, a narrower term within Myocardial Ischemia.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Aarhus University Hospital Skejby · Not applicable, Interventional, and Diagnostic

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
122
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Coronary Artery Disease by Aarhus University Hospital Skejby — none open to participants now, 4 under way, none of them phase 3. Coronary Artery Disease · Aarhus University Hospital Skejby.

Enrollment
11th of 15
122 · median 425
Started
2022
the only one that year
No phase
11 of 18
none open now
Registered
18th of 18
by date

Among the 18 studies in Coronary Artery Disease by Aarhus University Hospital Skejby, this one is the 11th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2022, is one of 11 with no phase, and was the 18th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

None of the 18 studies in Coronary Artery Disease by Aarhus University Hospital Skejby is open now. The open studies under Coronary Artery Disease, anywhere →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies in Coronary Artery Disease by Aarhus University Hospital Skejby as a file.
02

Study summary

Coronary computed tomography angiography (CCTA) is a non-invasive method for visualization of the coronary arteries. The anatomical information obtained by CCTA, however, is rarely integrated into a subsequent coronary intervention. The CT-FOCI trial aims to evaluate, in a randomized setting, the benefit of implementing the information obtained by CCTA as part of the invasive examination using a CT-guided algorithm (CTGA). Patients (n=120) with symptoms of stable angina pectoris will be randomized 1:1 after CCTA has determined at least 1 stenosis with luminal diameter reduction of minimum 50% in a vessel segment > 2 mm in diameter. Subsequent, invasive examination and intervention will utilize the information available according to randomization. Primary efficacy endpoints are a reduction in patient radiation exposure, procedure time, procedural utensils, and contrast use.

Secondary endpoints is significant stenosis in the non-target vessel, only available in the conventional group.

Read the detailed description

The study is a randomized, single center trial. Patients (n=120) referred for CCTA due to symptoms suggesting obstructive coronary disease (shortness of breath on exertion or angina in relation to activity), are randomized 1:1 if CCTA finds coronary lesions suggestive of obstructive coronary artery disease in at lest one vessel and thus indication for further investigation by invasive examination.

The patients are randomized to a standard treatment (ST) and a protocol with a CT-guided algorithm (CTGA) for optimal interventional work-flow. ST includes the use of two diagnostic cathers and examination of both coronary arteries by at least 6 different standard projections best optimizing the view of the coronary lesions. Additional projections may be included if deemed necessary for optimal angiographic evaluation. Procedural time consumption (timepoint 1) is measured at the completion of the angiogram as specified (7.4.2). If there is a switch to a guiding catheter and subsequent coronary physiology test (fractional flow reserve [FFR]) this is marked at timepoint 2 at the conclusion of the FFR.

In the CTGA group only the artery suspected of having obstructive coronary disease is examined. Anatomy of the vessel, optimal viewing projections and choice of catheter is determined. A guiding catheter is used as first choice based on the artery involved and the aortic anatomy. Time is recorded according to the ST group, with timepoint 1 after conclusion of the angiogram, timepoint 2 after FFR.

On the day of invasive examination, the total amount of contrast, radiation dose, procedural time consumption and cost of utensils are registered as primary endpoints. In the conventional group, any significant stenosis in the non-target vessel

03

Conditions studied

  • Ischemic Heart Disease
  • Coronary Artery Disease

Browse trials for

Keywords

  • CCTA
04

In context

Coronary Artery Disease Reclassified

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

This study's enrollment of 122 is close to the median of 123 across 3,011 interventional studies indexed under Coronary Artery Disease.

Browse Coronary Artery Disease studies →

Lead sponsor

Aarhus University Hospital Skejby is the lead sponsor of 60 studies on the registry; 3 are open to participants now.

Compared within Coronary Artery Disease, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Myocardial Ischemia. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age > 18 and \< 81 years
  • Stable angina
  • at least 1 vessel disease in either the left coronary artery or right coronary artery
  • Stenosis grater than 50% and no stenosis greater than 40% on contralateral vessel unless fractional flow reserve by CT (FFRct) >0.80
  • Vessel segment > 2 mm in diameter
  • Subject eligible for Dual Anti Therapy (DAPT

Exclusion criteria

Exclusion Criteria:

  • Significant bleeding risk or other against heparinization or DAPT
  • Known pregnancy
  • \< 120 days
  • Patient unable to provide
  • Patients with CTO (Chronic Total Occlusion).
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
122 participants (actual)

Study arms

  • Experimental
    CT-guided algorithm (CTGA)

    In the CTGA group only the artery suspected of having obstructive coronary disease is examined. Anatomy of the vessel, optimal viewing projections and choice of catheter is determined. A guiding catheter is used as first choice based on the artery involved and the aortic anatomy. Time is recorded according to the ST group, with timepoint 1 after conclusion of the angiogram, timepoint 2 after FFR.

    Diagnostic Test: CCTA guided focused coronary angiography examination.

  • No intervention
    Standard treatment (ST)

    ST includes the use of two diagnostic cathers and examination of both coronary arteries by at least 6 different standard projections best optimizing the view of the coronary lesions. Additional projections may be included if deemed necessary for optimal angiographic evaluation

Interventions

  • Diagnostic testCCTA guided focused coronary angiography examination.

    Focused examination based on Images from CCTA, by choice of optimal catheter used and projection.

07

What researchers measure

Primary outcomes

  1. Patient radiation dose

    After coronary angiography and percutaneous coronary intervention (PCI), the Dose Area Product (DAP) Gycm2 and the radiation time (MM:SS) is recorded.

    Time frame: Through angiography completion, an average of 4-5 minuets. Timepoint 1

  2. Procedure time

    The procedure time is defined at the time from first catheter insertion to final catheter removal. Time is recorded in MM:SS.

    Time frame: Through angiography completion, an average of 4-5 minuets. Timepoint 1

  3. Contrast use

    The amount of contrast medium used for examination and intervention is measured (ml) by weight measurements (gram = ml).

    Time frame: Through angiography completion, an average of 4-5 minuets. Timepoint 1

  4. utensils use

    The use of utensils are logged and a cost estimate subsequently calculated on the basis of the current price list (DKK/USD).

    Time frame: Through angiography completion, an average of 4-5 minuets. Timepoint 1

Secondary outcomes

  1. Stenosis in non-target vessel

    Significant stenosis in non-target vessel, (only conventional grope), confirmed by FFR \<0.80

    Time frame: Through angiography completion, an average of 4-5 minuets. Timepoint 1

08

Study locations

1 site
  • Aarhus University Hospital, Depart. of Cardiology
    Aarhus N, Central Region 8200, Denmark
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in Feb 2025, 33 months.

Of 756 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's 33 months is close to that.

Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2021
First posted
Feb 1, 2022
StartActual
May 1, 2022
Primary completionActual
Feb 28, 2025
CompletionActual
Feb 28, 2025
Last update
Aug 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05218694
Lead sponsor
Aarhus University Hospital Skejby
Responsible party
Nicolaj Brejnholt Støttrup (MD, Ph.D., Aarhus University Hospital Skejby) — Principal investigator
First posted
Feb 1, 2022
Start date
May 1, 2022
Primary completion
Feb 28, 2025
Completion
Feb 28, 2025
Last update
Aug 26, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion